Stemcells Rises 6% in Early Trade on Progress With Test Treatment for Eye DisorderCatherine Kinney (Author) Published Date : May 29, 2014 18:40 ET
Stemcells Inc. (STEM) rose in early trading after announcing progress in a study of stem-cell treatment for vision disorders. The biotech company said it transplanted its purified human neural stem cells, named HuCNS-SC, into five patients as part of a test treatment for age-related macular degeneration. The trial is intended to evaluate the safety and effectiveness of HuCNS-SC cells in treating patients with impaired vision. The patients received a dose of 1 million stem cells injected into the eye. Stemcells rose 6% in pre-market trading to $1.41 a share. It reached a two-year low of $1.15 during regular trading on April 15.
Stemcells Rises 6% in Early Trade on Progress With Test Treatment for Eye Disorder